Ниже ответы, которые я получил от зарубежных коллег по PedNeph (аналог Nephrol для педиатров) Резюме: у больных с ХБП 4-5 и на диализе Тамифлю применять можно но дозы должны быть уменьшены и\или назначаться через более долгий интервал.
Доза для здорового взрослого 75 мг х 2 р в день - 5 дней.
Одна из рекомендаций для больных на гемодиализе: половина суточной дозы 1 раз в день.
Другая рекомендация :У пациентов с клубочковой фильтрацией от 10 до 30 мл\мин- 75 мг 1 раз в день.
У пациентов на ПД - 30 мг 1 раз в неделю.
У пациентов на гемодиализе 30 мг через 1 час после каждого сеанса гемодиализа.
Dear Dr. Kagan,
It is possible to use Tamiflu in dialysis. We have used it in children at reduced doses and much longer intervals.
There are not very serious toxicity, so the drug seems very safe.
See attached paper for details.
Tom Nevins
Tom Nevins
Pediatrics
MMC #491
420 Delaware Street SE
Minneapolis, MN 55455
The recommendations are 50% of the normal daily dose, and just one dose,
not two divided doses. I started a couple of our dialysis patients with
influenza-like illness (ILI) on that regime and we had not problems. One
H1N1 transplant patient had to be admitted with his ILI with a pneumonia
and dehydration on Ozeltamovir treatment.
Best wishes,
Guido
Guido Filler, MD, PhD, FRCPC
Professor of Paediatrics
Chair/Chief, Department of Paediatrics
Children's Hospital, London Health Science Centre
University of Western Ontario
800 Commissioners Road East
London, ON, N6A 5W9
Canada
Dear Mikhail,
Yes, you can use it with a dose tampering.
If your e-mail supports HTML you should be able to read the RxList citation below.
If not, let me know – I’ll try to convert it somehow.
Best regards,
Vladimirs Strazdins
Riga, Latvia
Special Populations
Renal Impairment
Administration of 100 mg of oseltamivir phosphate twice daily for 5 days to patients with various degrees of renal impairment showed that exposure to oseltamivir carboxylate is inversely proportional to declining renal function. Oseltamivir carboxylate exposures in patients with normal and abnormal renal function administered various dose regimens of oseltamivir are described in Table 2.
Table 2: Oseltamivir Carboxylate Exposures in Patients With Normal and Reduced Serum Creatinine Clearance
Parameter
Normal Renal Function
Impaired Renal Function
75 mg qd
75 mg bid
150 mg bid
Creatinine Clearance
<10 mL/min
Creatinine Clearance
>10 and <30 mL/min
CAPD
Hemodialysis
75 mg daily
75 mg alternate days
30 mg daily
30 mg weekly
30 mg alternate HD cycle
Cmax
259*
348*
705*
766
850
1638
1175
655
Cmin
39*
138*
288*
62
48
864
209
346
AUC48
7476*
1 0876*
21864*
17381
12429
62636
21999
25054
*Observed values.All other values are predicted.
AUC normalized to 48 hours.
Hepatic Impairment
In clinical studies oseltamivir carboxylate exposure was not altered in patients with mild or moderate hepatic impairment (see PRECAUTIONS: Hepatic Impairment and DOSAGE AND ADMINISTRATION).
Pediatric Patients
The pharmacokinetics of oseltamivir and oseltamivir carboxylate have been evaluated in a single dose pharmacokinetic study in pediatric patients aged 5 to 16 years (n=18) and in a small number of pediatric patients aged 3 to 12 years (n=5) enrolled in a clinical trial. Younger pediatric patients cleared both the prodrug and the active metabolite faster than adult patients resulting in a lower exposure for a given mg/kg dose. For oseltamivir carboxylate, apparent total clearance decreases linearly with increasing age (up to 12 years). The pharmacokinetics of oseltamivir in pediatric patients over 12 years of age are similar to those in adult patients.
Vladimirs Strazdins, MD
Dear Mikhail,
Here is another sample from the manufacturer's website:
RENAL IMPAIRMENT DOSING* (for patients with creatinine clearance between 10
mL/min and 30 mL/min)
Treatment dosing 75 mg once daily for 5 days
Prophylaxis dosing 75 mg every other day or 30 mg oral suspension once daily 1
*No recommended dosing regimens are available for patients undergoing routine
hemodialysis and continuous peritoneal dialysis treatment with end-stage renal
disease.
PEDIATRIC (1-12 years) DOSING BODY WEIGHT lbs (kg) DOSAGE
Treatment dosing
?33 lbs (?15 kg) 30 mg/bid/5 days
>33 lbs to 51 lbs (>15 kg to 23 kg) 45 mg/bid/5 days
>51 lbs to 88 lbs (>23 kg to 40 kg) 60 mg/bid/5 days
>88 lbs (>40 kg) 75 mg/bid/5 days
Prophylaxis dosing
?33 lbs (?15 kg) 30 mg/qd/10 days
>33 lbs to 51 lbs (>15 kg to 23 kg) 45 mg/qd/10 days
>51 lbs to 88 lbs (>23 kg to 40 kg) 60 mg/qd/10 days
>88 lbs (>40 kg) 75 mg/qd/10 days
Vladimirs Strazdins, MD